As announced this summer by Philips and Toronto-based Profound Medical, the two companies will integrate Profound’s TULSA (Transurethral Ultrasound Ablation) technology onto Philips’ 3T MRI systems. TULSA is designed to provide minimally invasive, single session whole gland ablation for patients with prostate cancer.
“Philips has stepped forward and enthusiastically shares our vision for the technology. With their support, TULSA-PRO will soon be available to clinicians and patients for primary treatment of localized prostate cancer,” says Steve Plymale, Profound Medical’s CEO. “This new relationship will provide us with access to a large installed base of MRI systems and customers, and we look forward to developing this mutually rewarding relationship further.”
Profound’s novel technology combines real-time MRI imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery.
Having recently raised $28M and gone public in June 2015, Profound will commence its pivotal trial of 110 patients and prepare for its 2016 European and Canadian launch.